Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 150 articles: HTML format

Single Articles

October 2026
1. BARRATT J, Farag YMK, Rice K, Cammett TJ, et al
   Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
   N Engl J Med. 2026 Oct 23. doi: 10.1056/NEJMoa2607544.
   PubMed     Abstract available
   
   
   
2. BARRATT J, Zhang H, Han SH, Suzuki Y, et al
   Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
   N Engl J Med. 2026 Oct 23. doi: 10.1056/NEJMoa2608682.
   PubMed     Abstract available
   
   
   
3. RIZK DV, Barratt J, Suzuki Y, Zhang H, et al
   Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis.
   N Engl J Med. 2026 Oct 22. doi: 10.1056/NEJMoa2609127.
   PubMed     Abstract available
   
   
   
4. BARRATT J, Brenner RM, Barbour SJ, Campbell KN, et al
   Atacicept in IgA Nephropathy - Phase 3 Trial Final Efficacy Analysis.
   N Engl J Med. 2026 Oct 22. doi: 10.1056/NEJMoa2610103.
   PubMed     Abstract available
   
   
   
5. FURIE RA, Vital EM, Meier O
   Obinutuzumab in Active Systemic Lupus Erythematosus. Reply.
   N Engl J Med. 2026;395:1562.
   PubMed    
   
   
   
6. PAMUK ON
   Obinutuzumab in Active Systemic Lupus Erythematosus.
   N Engl J Med. 2026;395:1562.
   PubMed    
   
   
   
7. UHLIG HH, Hambleton S, Travis S
   Interleukin-10 Autoantibodies in Inflammatory Bowel Disease. Reply.
   N Engl J Med. 2026;395:1459.
   PubMed    
   
   
   
8. BAI X, Xu C, Yang H
   Interleukin-10 Autoantibodies in Inflammatory Bowel Disease.
   N Engl J Med. 2026;395:1458-1459.
   PubMed    
   
   
   
9. KUCUK H, Erden A, Tufan A
   Interleukin-10 Autoantibodies in Inflammatory Bowel Disease.
   N Engl J Med. 2026;395:1458.
   PubMed    
   
   
   
10. ANTONIOLI L
    Interleukin-10 Autoantibodies in Inflammatory Bowel Disease.
    N Engl J Med. 2026;395:1457-1458.
    PubMed    
    
    
    
11. DELLA-TORRE E, Baker MC, Zhang W, Perugino CA, et al
    Obexelimab for the Treatment of IgG4-Related Disease.
    N Engl J Med. 2026;395:1273-1284.
    PubMed     Abstract available
    
    
    September 2026
12. SOLER MJ
    A Step Forward - Obinutuzumab for Membranous Nephropathy.
    N Engl J Med. 2026;395:1024-1026.
    PubMed    
    
    
    
13. ZHANG Y, Lv J, Zhang H
    Telitacicept for IgA Nephropathy. Reply.
    N Engl J Med. 2026;395:932-933.
    PubMed    
    
    
    
14. MUHAMMAD A, Yuan L, Xiao X
    Telitacicept for IgA Nephropathy.
    N Engl J Med. 2026;395:932.
    PubMed    
    
    
    
15. HUNG MH, Cheng SY
    Telitacicept for IgA Nephropathy.
    N Engl J Med. 2026;395:931-932.
    PubMed    
    
    
    
16. CHENG YH, Shang K, Qin C, Dong MH, et al
    Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders.
    N Engl J Med. 2026;395:926-929.
    PubMed    
    
    
    August 2026
17. IPENBURG NA, Sangers TE
    Drug-Induced Subacute Cutaneous Lupus Erythematosus.
    N Engl J Med. 2026;395:e10.
    PubMed    
    
    
    
18. KAYASHIMA A, Horibe M
    Type 1 Autoimmune Pancreatitis.
    N Engl J Med. 2026;395:592.
    PubMed    
    
    
    July 2026
19. SCHETT G, Wirsching A, Rothe T, Visconti V, et al
    Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy.
    N Engl J Med. 2026 Jul 29. doi: 10.1056/NEJMc2607737.
    PubMed    
    
    
    
20. WARKENTIN TE, Greinacher A
    Platelet-Activating Anti-Platelet Factor 4 Disorders.
    N Engl J Med. 2026 Jul 13. doi: 10.1056/NEJMra2502459.
    PubMed     Abstract available
    
    
    
21. HAUSER SL
    Advances in Multiple Sclerosis.
    N Engl J Med. 2026;395:54-68.
    PubMed     Abstract available
    
    
    
22. TORKILDSEN O, Brustad HK, Hogestol EA, Alstadhaug KB, et al
    Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
    N Engl J Med. 2026;395:44-53.
    PubMed     Abstract available
    
    
    June 2026
23. BASTARD P, Casanova JL
    Autoantibodies against Cytokines - From Infection to Inflammation.
    N Engl J Med. 2026;394:2270-2273.
    PubMed    
    
    
    
24. GHARAHDAGHI N, Yeh PJ, Ceron-Gutierrez L, Griffin H, et al
    Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.
    N Engl J Med. 2026;394:2212-2222.
    PubMed     Abstract available
    
    
    
25. FERVENZA FC, Hou FF, Hao CM, Kirsztajn GM, et al
    Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.
    N Engl J Med. 2026 Jun 5. doi: 10.1056/NEJMoa2602678.
    PubMed     Abstract available
    
    
    May 2026
26. ALLENBACH Y, Benveniste O
    Inflammatory Myopathies.
    N Engl J Med. 2026;394:1925-1938.
    PubMed     Abstract available
    
    
    
27. LV J, Liu L, Wang W, Wang X, et al
    Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
    N Engl J Med. 2026;394:1916-1924.
    PubMed     Abstract available
    
    
    
28. LAFAYETTE R, Brenner RM, Barratt J
    Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy. Reply.
    N Engl J Med. 2026;394:1962-1963.
    PubMed    
    
    
    
29. KA SM, Chen A, Wu CC
    Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy.
    N Engl J Med. 2026;394:1962.
    PubMed    
    
    
    
30. LUNDBERG IE
    A Phase 3 Trial of Brepocitinib in Dermatomyositis.
    N Engl J Med. 2026;394:1953-1955.
    PubMed    
    
    
    April 2026
31. KAWANO N, Kikuchi I
    Membranoproliferative Glomerulonephritis Due to Cryoglobulinemia.
    N Engl J Med. 2026;394:1736.
    PubMed    
    
    
    
32. CUKER A, Stauch T, Cooper N, Al-Samkari H, et al
    Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
    N Engl J Med. 2026;394:1503-1513.
    PubMed     Abstract available
    
    
    
33. CERQUEIRA-SILVA T, Paixao E, Franca GVA, Tenorio LXS, et al
    Risk of Guillain-Barre Syndrome after Laboratory-Confirmed Dengue Infection.
    N Engl J Med. 2026;394:1546-1548.
    PubMed    
    
    
    
34. MURRAY JA, Husby S
    Celiac Disease.
    N Engl J Med. 2026;394:1421-1429.
    PubMed     Abstract available
    
    
    
35. KUTER DJ, Miura K, Patriarca A, Pulanic D, et al
    A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
    N Engl J Med. 2026;394:1388-1398.
    PubMed     Abstract available
    
    
    
36. XIONG H, Li R, Shi J
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.
    N Engl J Med. 2026;394:1455.
    PubMed    
    
    
    
37. YANG S, Lu Y
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
    N Engl J Med. 2026;394:1455.
    PubMed    
    
    
    March 2026
38. BARRATT J, Eren N, Kashihara N, Maes B, et al
    Iptacopan in IgA Nephropathy - Final 24-Month Data.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2600743.
    PubMed     Abstract available
    
    
    
39. VLEUGELS RA, Paik JJ, Bauer Ventura I, Mangold AR, et al
    A Phase 3 Trial of Brepocitinib in Dermatomyositis.
    N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2503531.
    PubMed     Abstract available
    
    
    
40. FURIE RA, Dall'Era M, Vital EM, Garg JP, et al
    Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.
    N Engl J Med. 2026 Mar 6. doi: 10.1056/NEJMoa2516150.
    PubMed     Abstract available
    
    
    
41. GOTTSCHLICH A, Bucklein V, El-Marouk K, Kaiser R, et al
    Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.
    N Engl J Med. 2026;394:1030-1033.
    PubMed    
    
    
    
42. HEERSPINK HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, et al
    Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    N Engl J Med. 2026;394:947-957.
    PubMed     Abstract available
    
    
    February 2026
43. TONELLI M
    Targeting the Pathogenesis of IgA Nephropathy - A New Treatment Approach?
    N Engl J Med. 2026;394:712-713.
    PubMed    
    
    
    January 2026
44. LI R, Pan H, Zhang L, Ma J, et al
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
    N Engl J Med. 2026;394:253-267.
    PubMed     Abstract available
    
    
    November 2025
45. PERKOVIC V, Trimarchi H, Tesar V, Lafayette R, et al
    Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512133.
    PubMed     Abstract available
    
    
    
46. LAFAYETTE R, Barbour SJ, Brenner RM, Campbell KN, et al
    A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
    N Engl J Med. 2025 Nov 6. doi: 10.1056/NEJMoa2510198.
    PubMed     Abstract available
    
    
    October 2025
47. SCOTT J, Abers MS, Marwah HK, McCann NC, et al
    Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.
    N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMsa2514268.
    PubMed     Abstract available
    
    
    
48. RAHIMOV F, Jacobs BM, Lee JS, Mahi NA, et al
    Common Diseases in Clinical Cohorts - Not Always What They Seem.
    N Engl J Med. 2025;393:1589-1598.
    PubMed     Abstract available
    
    
    
49. VAN VOLLENHOVEN RF, Wang L, Merrill JT, Liu Y, et al
    A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
    N Engl J Med. 2025;393:1475-1485.
    PubMed     Abstract available
    
    
    
50. BUCCI L, Boltz S, Hagen M, Tur C, et al
    BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
    N Engl J Med. 2025;393:1544-1547.
    PubMed    
    
    
    September 2025
51. WANG Q, Xiao ZX, Zheng X, Wang G, et al
    In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus.
    N Engl J Med. 2025 Sep 17. doi: 10.1056/NEJMc2509522.
    PubMed    
    
    
    
52. CARLSSON PO, Hu X, Scholz H, Ingvast S, et al
    Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.
    N Engl J Med. 2025;393:887-894.
    PubMed     Abstract available
    
    
    August 2025
53. TRAPNELL BC, Inoue Y, Bonella F, Wang T, et al
    Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.
    N Engl J Med. 2025;393:764-773.
    PubMed     Abstract available
    
    
    
54. SEYMOUR JF
    GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis.
    N Engl J Med. 2025;393:812-816.
    PubMed    
    
    
    July 2025
55. FURIE RA, Rovin BH, Pendergraft WF 3rd
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Reply.
    N Engl J Med. 2025;393:410.
    PubMed    
    
    
    
56. DE FREMONT GM, Le Guern V, Costedoat-Chalumeau N
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:409-410.
    PubMed    
    
    
    
57. KARASSA FB
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:409.
    PubMed    
    
    
    
58. SAHUTOGLU T
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:408-409.
    PubMed    
    
    
    
59. ANGELETTI A, Marasa M, Cravedi P
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:408.
    PubMed    
    
    
    June 2025
60. REICHMAN TW, Markmann JF, Odorico J, Witkowski P, et al
    Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
    N Engl J Med. 2025 Jun 20. doi: 10.1056/NEJMoa2506549.
    PubMed     Abstract available
    
    
    
61. WOLFE GI, Shelly S
    Myasthenia Gravis - Redemption for B-Cell Depletion.
    N Engl J Med. 2025;392:2382-2384.
    PubMed    
    
    
    
62. ZHANG L, Gao Z, Pan H, Li R, et al
    BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.
    N Engl J Med. 2025;392:2282-2284.
    PubMed    
    
    
    May 2025
63. KOSTER MJ, Warrington KJ
    Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis.
    N Engl J Med. 2025;392:2062-2064.
    PubMed    
    
    
    
64. BARRATT J, Perkovic V, Rizk DV
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. Reply.
    N Engl J Med. 2025;392:1976.
    PubMed    
    
    
    
65. ANGELETTI A, Marasa M, Cravedi P
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
    N Engl J Med. 2025;392:1976.
    PubMed    
    
    
    
66. POPPELAARS F, Faria B, Thurman JM
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
    N Engl J Med. 2025;392:1975.
    PubMed    
    
    
    
67. CALABRESI PA
    Progress toward Mitigating Disability Progression in Multiple Sclerosis.
    N Engl J Med. 2025;392:1966-1968.
    PubMed    
    
    
    
68. HOSHINO Y, Okamoto K, Ito N
    More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.
    N Engl J Med. 2025;392:1871-1872.
    PubMed    
    
    
    
69. MINISOLA S, Pepe J, Cipriani C
    More on Acquired Osteomalacia and Autoantibodies against PHEX.
    N Engl J Med. 2025;392:1871.
    PubMed    
    
    
    April 2025
70. FAVA A
    To B or Not to B - the Role of B-Cell Depletion in Lupus Nephritis.
    N Engl J Med. 2025;392:1545-1547.
    PubMed    
    
    
    
71. FOX RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, et al
    Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415988.
    PubMed     Abstract available
    
    
    
72. OH J, Arnold DL, Cree BAC, Ionete C, et al
    Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415985.
    PubMed     Abstract available
    
    
    
73. NOWAK RJ, Benatar M, Ciafaloni E, Howard JF Jr, et al
    A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2501561.
    PubMed     Abstract available
    
    
    
74. BLOCKMANS D, Penn SK, Setty AR, Schmidt WA, et al
    A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
    N Engl J Med. 2025 Apr 2. doi: 10.1056/NEJMoa2413449.
    PubMed     Abstract available
    
    
    March 2025
75. STONE JH, Khosroshahi A, Zhang W, Della Torre E, et al
    Inebilizumab for Treatment of IgG4-Related Disease.
    N Engl J Med. 2025;392:1168-1177.
    PubMed     Abstract available
    
    
    February 2025
76. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed     Abstract available
    
    
    
77. FURIE RA, Rovin BH, Garg JP, Santiago MB, et al
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965.
    PubMed     Abstract available
    
    
    January 2025
78. HOSHINO Y, Okamoto K, Ogawa T, Kato H, et al
    Acquired Osteomalacia Associated with Autoantibodies against PHEX.
    N Engl J Med. 2025;392:513-515.
    PubMed    
    
    
    October 2024
79. PERKOVIC V, Barratt J, Rovin B, Kashihara N, et al
    Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2410316.
    PubMed     Abstract available
    
    
    
80. INGELFINGER JR
    Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMe2413288.
    PubMed    
    
    
    
81. HEERSPINK HJL, Jardine M, Kohan DE, Lafayette RA, et al
    Atrasentan in Patients with IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409415.
    PubMed     Abstract available
    
    
    
82. CHANTRAPITAK J, Chuamanochan M
    Intertriginous Rash in Secondary Syphilis.
    N Engl J Med. 2024;391:e28.
    PubMed    
    
    
    
83. TOMAS NM, Hengel FE, Huber TB
    Autoantibodies Targeting Nephrin in Podocytopathies. Reply.
    N Engl J Med. 2024;391:1367-1368.
    PubMed    
    
    
    
84. BRUSCHI M, Angeletti A, Ghiggeri GM
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1366.
    PubMed    
    
    
    
85. BERG AH, Karumanchi SA
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365-1366.
    PubMed    
    
    
    
86. GLEESON PJ, Monteiro RC
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365.
    PubMed    
    
    
    September 2024
87. RUSSO G, Alipour Tehrany Y
    Discoid Lupus Erythematosus.
    N Engl J Med. 2024;391:e24.
    PubMed    
    
    
    
88. SALVARANI C, Hunder GG, Brown RD Jr
    Primary Central Nervous System Vasculitis.
    N Engl J Med. 2024;391:1028-1037.
    PubMed    
    
    
    
89. HAGEN M, Bucci L, Boltz S, Nothling DM, et al
    BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.
    N Engl J Med. 2024;391:867-869.
    PubMed    
    
    
    
90. ALEXANDER T, Kronke J, Cheng Q, Keller U, et al
    Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.
    N Engl J Med. 2024;391:864-866.
    PubMed    
    
    
    August 2024
91. GRIFFIN H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, et al
    Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
    N Engl J Med. 2024;391:434-441.
    PubMed     Abstract available
    
    
    July 2024
92. LI M, Zhang Y, Jiang N, Ning C, et al
    Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.
    N Engl J Med. 2024;391:376-378.
    PubMed    
    
    
    
93. WANG WY, Lin MC
    Chilblain Lupus Erythematosus.
    N Engl J Med. 2024;391:e6.
    PubMed    
    
    
    
94. CHENG A, Holland SM
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. Reply.
    N Engl J Med. 2024;391:189-190.
    PubMed    
    
    
    
95. ROSMARIN D, Amara S, Lebwohl M
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:189.
    PubMed    
    
    
    
96. COHEN JM, Damsky W
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:188-189.
    PubMed    
    
    
    
97. FEREDJ E, Cobat A, Casanova JL
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:187-188.
    PubMed    
    
    
    June 2024
98. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
99. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
100. WENSTEDT EFE, Vogt L
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:2226.
     PubMed    
     
     
     
101. CHEN Y, Xu Y, Li H, Sun T, et al
     A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
     N Engl J Med. 2024;390:2178-2190.
     PubMed     Abstract available
     
     
     May 2024
102. WECHSLER ME, Fan Y, Merkel PA
     Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
     N Engl J Med. 2024;390:1940.
     PubMed    
     
     
     
103. SUN R, Wei LJ
     Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
     N Engl J Med. 2024;390:1939.
     PubMed    
     
     
     
104. OIKONOMOU V, Smith G, Constantine GM, Schmitt MM, et al
     The Role of Interferon-gamma in Autoimmune Polyendocrine Syndrome Type 1.
     N Engl J Med. 2024;390:1873-1884.
     PubMed     Abstract available
     
     
     
105. SU MA
     JAK Inhibition Immunotherapy for APS-1.
     N Engl J Med. 2024;390:1918-1921.
     PubMed    
     
     
     
106. HENGEL FE, Dehde S, Lasse M, Zahner G, et al
     Autoantibodies Targeting Nephrin in Podocytopathies.
     N Engl J Med. 2024 May 25. doi: 10.1056/NEJMoa2314471.
     PubMed     Abstract available
     
     
     
107. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
     Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
     N Engl J Med. 2024;390:1827-1829.
     PubMed    
     
     
     
108. DOUGHTY CT, Schaefer PW, Brizzi K, Linnoila JJ, et al
     Case 14-2024: A 30-Year-Old Woman with Back Pain, Leg Stiffness, and Falls.
     N Engl J Med. 2024;390:1712-1719.
     PubMed    
     
     
     
109. MULLER F, Mackensen A, Schett G
     CAR T-Cell Therapy in Autoimmune Disease. Reply.
     N Engl J Med. 2024;390:1631-1632.
     PubMed    
     
     
     
110. HOWARD JF JR, Vu T, Mozaffar T
     CAR T-Cell Therapy in Autoimmune Disease.
     N Engl J Med. 2024;390:1629-1631.
     PubMed    
     
     
     
111. DE BENEDETTI F, Diomedi Camassei F, Locatelli F
     CAR T-Cell Therapy in Autoimmune Disease.
     N Engl J Med. 2024;390:1629.
     PubMed    
     
     
     
112. MERKT W, Lorenz HM, Schmitt M
     CAR T-Cell Therapy in Autoimmune Disease.
     N Engl J Med. 2024;390:1628-1629.
     PubMed    
     
     
     April 2024
113. MATHUR M, Barratt J, Suzuki Y
     Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. Reply.
     N Engl J Med. 2024;390:1245-1246.
     PubMed    
     
     
     
114. BELMONT HM
     Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
     N Engl J Med. 2024;390:1245.
     PubMed    
     
     
     
115. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:1207-1217.
     PubMed    
     
     
     March 2024
116. NETEA MG, van de Veerdonk FL
     Anti-Interleukin-23 Autoantibodies and Severe Infections.
     N Engl J Med. 2024;390:1143-1146.
     PubMed    
     
     
     
117. CHENG A, Kashyap A, Salvator H, Rosen LB, et al
     Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
     N Engl J Med. 2024;390:1105-1117.
     PubMed     Abstract available
     
     
     
118. DRIVENES JL, Bygum A
     Spontaneous Oral Purpura in Immune Thrombocytopenia.
     N Engl J Med. 2024;390:1029.
     PubMed    
     
     
     
119. WECHSLER ME, Nair P, Terrier B, Walz B, et al
     Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
     N Engl J Med. 2024;390:911-921.
     PubMed     Abstract available
     
     
     February 2024
120. MULLER F, Taubmann J, Bucci L, Wilhelm A, et al
     CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
     N Engl J Med. 2024;390:687-700.
     PubMed     Abstract available
     
     
     
121. ISAACS JD
     CAR T Cells - A New Horizon for Autoimmunity?
     N Engl J Med. 2024;390:758-759.
     PubMed    
     
     
     
122. HAUSER SL
     Silencing Immune Dialogue in Multiple Sclerosis.
     N Engl J Med. 2024;390:662-663.
     PubMed    
     
     
     
123. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
     Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
     N Engl J Med. 2024;390:589-600.
     PubMed     Abstract available
     
     
     January 2024
124. DANDONA P, Chaudhuri A, Ghanim H
     More on Semaglutide in Early Type 1 Diabetes. Reply.
     N Engl J Med. 2024;390:292.
     PubMed    
     
     
     
125. GAGLIA JL, Laffel LM, Patti ME
     More on Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2024;390:291.
     PubMed    
     
     
     
126. WEINRAUCH LA, D'Elia JA
     More on Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2024;390:291.
     PubMed    
     
     
     
127. DEVRIES JH
     More on Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2024;390:290.
     PubMed    
     
     
     
128. HADZIC N, Deheragoda M, Worth A, Bansal S, et al
     JAK Inhibition in STAT1 Gain-of-Function-Mediated Treatment-Resistant Autoimmune Hepatitis.
     N Engl J Med. 2024;390:284-286.
     PubMed    
     
     
     
129. LEE TTM, Bergford S, Murphy HR
     Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
     N Engl J Med. 2024;390:184.
     PubMed    
     
     
     
130. GRZYCH G, Kim I
     Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
     N Engl J Med. 2024;390:183-184.
     PubMed    
     
     
     
131. VIVANTI AJ, Benachi A, Voican A
     Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
     N Engl J Med. 2024;390:183.
     PubMed    
     
     
     
132. LEMLEY KV, Glassock RJ
     APRIL - Springtime for New IgA Nephropathy Therapy?
     N Engl J Med. 2024;390:80-81.
     PubMed    
     
     
     
133. LIU MJ, Li J
     Necrobiosis Lipoidica.
     N Engl J Med. 2024;390:70.
     PubMed    
     
     
     December 2023
134. ARJUNAN D, Bhadada SK
     Thyroid Dermopathy in Graves' Disease.
     N Engl J Med. 2023;389:2376.
     PubMed    
     
     
     
135. LUDVIGSSON J
     Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
     N Engl J Med. 2023;389:2199-2201.
     PubMed    
     
     
     
136. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
     Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
     N Engl J Med. 2023;389:2140-2150.
     PubMed     Abstract available
     
     
     November 2023
137. EL-ZAATARI ZM
     Anti-Glomerular Basement Membrane Glomerulonephritis.
     N Engl J Med. 2023;389:1901.
     PubMed    
     
     
     
138. BUSSEL JB, Hou M, Cines DB
     Primary Immune Thrombocytopenia in Pregnancy. Reply.
     N Engl J Med. 2023;389:1728.
     PubMed    
     
     
     
139. TRAN BW, May KA, Pal N
     Primary Immune Thrombocytopenia in Pregnancy.
     N Engl J Med. 2023;389:1728.
     PubMed    
     
     
     
140. MATHUR M, Barratt J, Chacko B, Chan TM, et al
     A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
     N Engl J Med. 2023 Nov 2. doi: 10.1056/NEJMoa2305635.
     PubMed     Abstract available
     
     
     October 2023
141. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
     Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
     N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
     PubMed     Abstract available
     
     
     
142. LINDHOFF-LAST E, Schonborn L, Zaninetti C, Warkentin TE, et al
     Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder.
     N Engl J Med. 2023;389:1339-1341.
     PubMed    
     
     
     
143. SPIERA RF, Unizony S, Warrington KJ, Sloane J, et al
     Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
     N Engl J Med. 2023;389:1263-1272.
     PubMed     Abstract available
     
     
     
144. LEE TTM, Collett C, Bergford S, Hartnell S, et al
     Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
     N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
     PubMed     Abstract available
     
     
     
145. GARG SK, Polsky S
     Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
     N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
     PubMed    
     
     
     
146. ALETAHA D
     Polymyalgia Rheumatica - from Search for Efficacy to Choice of Strategy.
     N Engl J Med. 2023;389:1328-1329.
     PubMed    
     
     
     September 2023
147. BRODERICK L, Kastner DL
     Variant STAT4 and Treatment of an Autoinflammatory Syndrome. Reply.
     N Engl J Med. 2023;389:1151-1152.
     PubMed    
     
     
     
148. PASTORE S, De Martino E, Taddio A
     Variant STAT4 and Treatment of an Autoinflammatory Syndrome.
     N Engl J Med. 2023;389:1151.
     PubMed    
     
     
     
149. WANG WY, Cheng ST
     Sleeve Sign and Inverse Gottron's Papules in Anti-MDA5 Dermatomyositis.
     N Engl J Med. 2023;389:1032.
     PubMed    
     
     
     
150. DANDONA P, Chaudhuri A, Ghanim H
     Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2023;389:958-959.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum